UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Pennsylvania 23-1210010 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) (Mark One) 530 Herman O. West Drive, Exton, PA 19341-0645 ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Address of principal executive offices) (Zip Code) For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d ...

Third-Quarter 2022 WST Q3 2022 Earnings 1 Third Quarter Overall Net Sales $686.9M | 2.8% Diluted Earnings Per Share: $1.59 Adjusted Diluted Earnings Per Share: $2.03 "While our base, non-COVID-19 demand continues to grow, we have had multiple constraints that impacted our financial results. Delays in expansion projects as well as customer delivery timing and mix-shift related productivity impacts resulted in lower-than-expected overall high-value product (HVP) net sales. We expect to resolve these issues in ...

West Pharmaceutical Services, Inc. (NYSE:WST) Q3 2022 Earnings Conference Call October 27, 2022 9:00 AM ET Company Participants Quintin Lai – Vice President-Investor Relations Eric Green – Chief Executive Officer Bernard Birkett – Chief Financial Officer Conference Call Participants Paul Knight – KeyBanc Larry Solow – CJS Securities Derik DeBruin – Bank of America Dave Windley – Jefferies Jacob Johnson – Stephens Operator Good day and thank you for standing by. Welcome to the Q3 2022 West Pharmaceutical Ser ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 23-1210010 (State or ot ...

West Pharmaceutical Services, Inc. (NYSE:WST) Q2 2022 Earnings Conference Call July 28, 2022 9:00 AM ET Company Participants Quintin Lai – Vice President, Investor Relations Eric Green – Chief Executive Officer Bernard Birkett – Chief Financial Officer Conference Call Participants Derik de Bruin – Bank of America Paul Knight – KeyBanc Larry Solow – CJS Securities Justin Lin – William Blair Jacob Johnson – Stephens Dave Windley – Jefferies Operator Good day, and thank you for standing by. Welcome to the Q2 2 ...

Second-Quarter 2022 WST Q2 2022 Earnings 1 Second Quarter Overall Net Sales $771.3M | 6.6% Diluted Earnings Per Share: $2.48 Adjusted Diluted Earnings Per Share: $2.47 "We delivered excellent second-quarter results with Proprietary Products organic net sales growth in the high-teens, led by demand for our high-value products (HVPs)." "Our base business continues to be strong, reflecting our team's successful execution of strategic initiatives and dedication to improving patient lives. In the quarter, COVID- ...

Financial Performance - Consolidated net sales increased by $49.3 million, or 7.4%, for the three months ended March 31, 2022, compared to the same period in 2021, with an unfavorable foreign currency translation impact of $24.2 million[98] - Proprietary Products net sales rose by $57.6 million, or 10.6%, for the three months ended March 31, 2022, primarily driven by growth in high-value product offerings, despite a $20.6 million unfavorable foreign currency translation impact[99] - Contract-Manufactured Products net sales decreased by $8.4 million, or 6.6%, for the three months ended March 31, 2022, attributed to a decline in sales of components for diagnostic devices[100] - Consolidated gross profit increased by $12.7 million, or 4.7%, for the three months ended March 31, 2022, with a gross profit margin decrease of 1.0 percentage point compared to the same period in 2021[103] - Consolidated operating profit increased by $14.1 million, or 8.0%, for the three months ended March 31, 2022, totaling $189.7 million[117] - Adjusted consolidated operating profit margin was 26.4% for the three months ended March 31, 2022, compared to 26.7% in the same period in 2021[117] Research and Development - Consolidated R&D costs rose by $2.4 million, or 19.7%, for the three months ended March 31, 2022, due to increased research efforts for new product opportunities[107] Costs and Expenses - Consolidated SG&A costs increased by $3.2 million, or 4.0%, for the three months ended March 31, 2022, compared to the same period in 2021, totaling $83.4 million[109] - Proprietary Products SG&A costs decreased by $0.6 million, or 1.1%, primarily due to a higher allocation of functional spend to Cost of Goods Sold[110] - Contract-Manufactured Products SG&A costs increased by $1.1 million, or 29.7%, for the three months ended March 31, 2022[111] Cash Flow and Working Capital - Net cash provided by operating activities increased by $62.5 million for the three months ended March 31, 2022, totaling $151.2 million[126] - Cash and cash equivalents decreased to $667.7 million as of March 31, 2022, from $762.6 million at December 31, 2021[129] - Working capital decreased by $42.2 million, or 3.7%, as of March 31, 2022, compared to December 31, 2021[131] Tax and Interest - The company recorded a tax benefit of $8.9 million associated with stock-based compensation during the first quarter of 2022[94] - The provision for income taxes was $21.2 million for the three months ended March 31, 2022, with an effective tax rate of 11.3%[124] - Interest expense, net, increased by $0.1 million, or 5.6%, for the three months ended March 31, 2022, totaling $1.9 million[122] Operational Risks and Considerations - The company continues to monitor the impact of COVID-19 on operations, maintaining strong capital and financial resources despite challenges[93] - Key factors affecting actual results include sales demand, competition, supply chain interruptions, and regulatory approvals[144] - There is a dependence on third-party suppliers, including single-source suppliers for critical materials, which poses a risk to operations[144] - The company acknowledges the potential impact of losing key personnel or skilled employees on its operational capabilities[144] - No material changes in market risk exposure have been reported since the last annual report[148] Forward-Looking Statements - The company emphasizes that forward-looking statements are based on current expectations and management's views, which may change over time[143] - Investors are cautioned against placing undue reliance on forward-looking statements due to inherent uncertainties[143] - The company does not undertake any obligation to publicly update forward-looking statements unless required by law[147] Product Development and Market Entry - The company recognizes the importance of customer product incorporation and the timing of commercialization for its products[144] - The company is focused on evaluating the functional, operational, clinical, and economic viability of its products for successful market entry[144]

West Pharmaceutical Services, Inc. (NYSE:WST) Q1 2022 Earnings Conference Call April 28, 2022 9:00 AM ET Company Participants Quintin Lai - VP, IR Eric Green - President and CEO Bernard Birkett - CFO Conference Call Participants Larry Solow - CJS Securities Justin Lin - William Blair Paul Knight - KeyBanc Jacob Johnson - Stephens Derik De Bruin - Bank of America Dave Windley - Jefferies Operator Good day and thank you for standing by. Welcome to the Q1 2022 West Pharmaceutical Services Earnings Conference C ...

First-Quarter 2022 First Quarter Overall Net Sales $720.0M | 7.4% Diluted Earnings Per Share: $2.29 | 15.1% Adjusted Diluted Earnings Per Share: $2.30| 12.2% WST Q1 2022 Earnings 1 "We delivered a solid first-quarter 2022 and remain on track to increase capacity throughout the year to satisfy the growing demand for our highvalue products (HVP)." "Our team members across the globe continue to demonstrate their passion to improve patient lives as they remain focused on executing our strategic initiatives desp ...

☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) Common Stock, par value $.25 per share W ...